What is the CJC-1295/Ipamorelin blend?

This blend combines CJC-1295 (a GHRH analog) with Ipamorelin (a selective ghrelin receptor agonist). They target two different receptor pathways that both lead to growth hormone release, producing a synergistic effect when used together.

Why combine CJC-1295 and Ipamorelin instead of using them separately?

CJC-1295 amplifies the GH release signal through the GHRH receptor, while Ipamorelin induces GH release through the ghrelin receptor. Together, they activate both the "amplifier" and "inducer" pathways, which research suggests produces stronger and more consistent GH pulsatility than either peptide alone.

Is this blend the same as CJC-1295 with DAC?

No. This blend uses CJC-1295 without DAC (also called Modified GRF 1-29), which has a shorter half-life and produces more physiological pulsatile GH release. CJC-1295 with DAC is a separate product with an extended half-life of 6-8 days due to albumin binding.

How should this blend be stored?

Lyophilized powder should be stored below -18°C, away from light and moisture. Once reconstituted with bacteriostatic water, refrigerate at 2-8°C and use within 28 days.

Is the CJC-1295/Ipamorelin blend FDA approved?

No. Neither CJC-1295 nor Ipamorelin is approved by the FDA. Both are prohibited by WADA under the S2 category. This blend is sold for laboratory and research purposes only.

-29%

4X Tested - ISO 17025

98.98% View COA

Growth Peptide Blend

CJC/ IPA BLEND

Certificate of Analysis

CJC-1295/Ipamorelin is a research blend combining a GHRH analog with a selective growth hormone secretagogue, studied for their synergistic activation of complementary growth hormone release pathways.

Size

Clear

BUNDLE & SAVE

1 Bottle $59.99 MOST POPULAR

2 Bottles $115.78

3+ Bottles $170.97

2-Day Shipping

Free Shipping
over $200

Free shipment
protection

Secure Checkout
256-bit SSL

Description

What is CJC/ IPA BLEND?

The CJC-1295/Ipamorelin blend combines two of the most widely studied growth hormone peptides in preclinical and clinical research: CJC-1295 (a synthetic GHRH analog) and Ipamorelin (a selective ghrelin receptor agonist).

These two peptides work through different but complementary receptor pathways. CJC-1295 acts as a GHRH receptor agonist on the pituitary gland, amplifying the growth hormone release signal. Ipamorelin acts as a ghrelin/GHS receptor agonist, inducing growth hormone release through a separate pathway. When combined, they stimulate GH release through both the “amplifier” (GHRH) and “inducer” (GHRP) mechanisms simultaneously.

This dual-pathway approach is one of the most commonly studied combinations in growth hormone research because it promotes stronger, more consistent pulsatile GH release than either peptide alone, while Ipamorelin’s high selectivity helps avoid unwanted elevations in cortisol, prolactin, or other hormones.

Neither component is approved by the FDA for any medical use. This blend is sold strictly for laboratory and research purposes only.

Research Applications

Areas of Investigation

Synergistic GH

Dual-Pathway GH Release

Combines GHRH receptor agonism (CJC-1295) with ghrelin receptor agonism (Ipamorelin) to stimulate growth hormone release through two complementary mechanisms simultaneously.

GH Pulsatility

Pulsatile GH Signaling

Studied for promoting natural pulsatile growth hormone release patterns, mimicking the body's physiological GH secretion rhythm more closely than either peptide alone.

IGF-1

IGF-1 Axis Research

Investigated for sustained elevations in IGF-1 levels through enhanced GH secretion, supporting downstream anabolic and regenerative signaling pathways.

Selectivity

Selective Endocrine Signaling

Ipamorelin's high receptor selectivity helps maintain clean GH stimulation without significant increases in cortisol, prolactin, or aldosterone — a key advantage over less selective secretagogues.

Compound Profile

Technical specifications

What is CJC/ IPA BLEND?

Molecular Profile

Sequence

CJC-1295: YADAIFTQSYRKVLA QLSARKLLQDILSR NH₂ Ipamorelin: Aib-His-D-2Nal-D-Phe-Lys NH₂

Molecular Formula

CJC-1295: C₁₅₂H₂₅₂N₄₄O₄₂ | Ipamorelin: C₃₈H₄₉N₉O₅

Molecular Weight

CJC-1295: 3,367.95 g/mol | Ipamorelin: 711.86 g/mol

Appearance

White lyophilized powder

Form

Lyophilized (freeze-dried)

Handling & Shelf Life Guidelines

Storage & Stability

Storage (Pre-Reconstitution)

Store below -18°C, desiccated, away from light and moisture.

Storage (Post-Reconstitution)

Refrigerate at 2-8°C. Stable for up to 28 days when reconstituted with bacteriostatic water. Avoid freeze-thaw cycles.

Shelf Life

24 months from date of manufacture when stored as directed

Sensitivity Notes

Sensitive to heat, light, and moisture. Keep sealed until use.

Compliance & Clinical Overview

Regulatory & Research Status

FDA Status

Not approved for human use. Neither component is FDA approved.

WADA Classification

Both components prohibited under class S2 (Peptide Hormones, Growth Factors).

Clinical Trial Status

Both peptides have extensive individual research on GH release, IGF-1 elevation, and body composition. Combination protocols are widely referenced in endocrine research literature.

Published Studies

Both peptides have extensive individual research on GH release, IGF-1 elevation, and body composition. Combination protocols are widely referenced in endocrine research literature.

Research Disclaimer

For laboratory and research purposes only. Not intended for human consumption.

COA's (Certificate of Analysis)

Third Party Tested by Freedom Diagnostics

98.98%

Purity

Variant

CJC/IPA BLEND

Lot #

GL-2609-008

Labelled

10mg

Actual

10.25mg

Tested

9/14/2026

View COA

(opens in a new tab)

99.08%